PNS126 COMPARING EARLY ACCESS TO UNLICENSED MEDICINES IN UK, FRANCE, AND SWEDEN: CONSISTENT PRINCIPLES BUT INCONSISTENT OUTPUTS.

The schemes in the UK, France and Sweden are the Early Access to Medicines Schemes (EAMS), cohort Temporary Authorization for Use (cohort-ATU) and Compassionate Use Program (CUP), respectively. Their main distinction relates to reimbursement: the cohort-ATU allows manufacturers to charge whereas under EAMS and CUP the manufacturer must provide for no charge. Conclusions The EAMS, CUP and cohort-ATU schemes appear to attract a largely distinct group of therapies and the cohort-ATU scheme has attracted over double and triple the drug:indication pairings than EAMS and CUP respectively. [Extracted from the article]